June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Use of Dexamethasone Intraocular Suspension 9% in Patients with Glaucoma: Results from a Retrospective Study
Author Affiliations & Notes
  • Paris Hanson
    Stony Brook University Renaissance School of Medicine, Stony Brook, New York, United States
  • Nicholas Tan
    SUNY Downstate Health Sciences University College of Medicine, Brooklyn, New York, United States
  • Nathaniel Tracer
    Maimonides Medical Center, Brooklyn, New York, United States
  • Nathan M Radcliffe
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
  • Footnotes
    Commercial Relationships   Paris Hanson, None; Nicholas Tan, None; Nathaniel Tracer, None; Nathan Radcliffe, Aerie (C), Alcon (C), Alimera (C), Allergan (C), B + L/Valleant (C), BVI (C), Carl Zeiss Meditec (C), CATS, LLC (C), Equinox (C), Eyenovia (C), Eyepoint (C), Glaukos (C), Iridex (C), Ivantis (C), Lumenis (C), New World Medical (C), Novartis (C), Omeros (C), Reichert (C), Shire (C), Sight Science (C), SpyGlass (C), Thea (C)
  • Footnotes
    Support  Research grant from EyePoint Pharmaceuticals
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3433. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paris Hanson, Nicholas Tan, Nathaniel Tracer, Nathan M Radcliffe; Use of Dexamethasone Intraocular Suspension 9% in Patients with Glaucoma: Results from a Retrospective Study. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3433.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To explore the real-world clinical outcomes in patients with a history of glaucoma treated with sustained-release dexamethasone intraocular suspension 9% for inflammation control following cataract surgery.

Methods : Retrospective data were collected from records of patients at multiple surgical sites who received dexamethasone intraocular suspension at the end of cataract surgery between Mar 12 and Dec 15, 2019. Anterior chamber cell (ACC) and intraocular pressure (IOP) at postop days 1, 8, 14, and 30 were summarized, along with minimally invasive glaucoma surgery (MIGS) procedures and number of concomitant IOP-lowering medications.

Results : 641 eyes of 527 patients treated with dexamethasone intraocular suspension were included in the study; glaucoma history was reported for 80 eyes of 66 patients. 15 of these eyes had a MIGS procedure; mean (SD) IOP-lowering medications per eye was 1.4 (0.53). For those with a record at each visit, mean (SD) IOP was 18.5 (8.50), 14.3 (4.34), 15.3 (3.31), and 14.4 (3.51) mmHg at postop days 1, 8, 14, and 30; ACC clearing at these timepoints was present in 52%, 68%, 82%, and 90% of eyes. In the full study population, IOP at the same timepoints was 18.6 (6.69), 15.2 (4.51), 15.1 (3.86), and 14.1 (3.84) mmHg; and 40%, 65%, 85%, and 90% of eyes had no ACC.

Conclusions : Results in this subset of eyes provide real-world insight into the use of a sustained release intraocular corticosteroid in patients with glaucoma undergoing cataract surgery; antiinflammatory efficacy and safety with regard to IOP elevation were similar to the full study population.

This is a 2021 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.